文献速递妇科

帕博利珠单抗联合聚乙二醇脂质体多柔比星治疗铂耐药卵巢癌:一项2期临床试验

Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
PubMed 文献 · Gynecol Oncol · 2020-08-06

本研究为单臂、多中心2期试验,纳入26例铂耐药卵巢癌患者,接受帕博利珠单抗200 mg静脉注射每3周一次联合聚乙二醇脂质体多柔比星40 mg/m²静脉注射每4周一次。23例可评估患者中12例获得临床获益,临床获益率为52.2%(95%CI 30.6-73.2%),达到主要终点;联合治疗耐受良好,无意外毒性。

要点

  • 23例可评估患者中临床获益率52.2%(95%CI 30.6-73.2%),达到主要终点。
  • 客观缓解率26.1%,包括5例部分缓解(21.7%)和1例完全缓解(4.3%)。
  • 联合治疗耐受良好,未出现意外毒性。

核心结论

  • 帕博利珠单抗联合聚乙二醇脂质体多柔比星治疗铂耐药卵巢癌可控,无意外毒性,并显示出初步临床获益证据。
  • 作者指出,本研究中联合治疗的客观缓解率和中位无进展生存期高于聚乙二醇脂质体多柔比星单药或抗PD-1/PD-L1药物单药的历史对照。

研究设计与样本

  • 单臂、多中心2期临床试验,纳入26例铂耐药卵巢癌患者,复发或持续性疾病既往细胞毒性治疗不超过2线。
  • 给药方案为帕博利珠单抗200 mg静脉注射每3周一次联合聚乙二醇脂质体多柔比星40 mg/m²静脉注射每4周一次,每8周进行影像学评估。
  • 主要终点为临床获益率,定义为完全缓解+部分缓解+疾病稳定≥24周;研究把握度设定为检测临床获益率从25%提高至50%,若至少10例患者获得临床获益则拒绝无效假设。
  • 评估T细胞炎症基因表达谱和PD-L1并与临床结局进行相关性分析。

主要发现

  • 23例患者可评估最佳总体缓解,12例获得临床获益,临床获益率52.2%(95%CI 30.6-73.2%),研究达到主要终点。
  • 5例部分缓解(21.7%),1例完全缓解(4.3%),客观缓解率26.1%。
  • 6例患者疾病稳定持续至少24周。
  • 联合治疗耐受良好,无意外毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pegylated liposomal doxorubicin (PLD) in vitro may have immunomodulatory abilities and preclinical evidence suggests it synergizes with immune checkpoint blockade. We hypothesized that combining PLD and pembrolizumab would be active in patients with platinum-resistant ovarian cancer (PROC). METHODS: This was a single-arm, multi-center phase II trial. Eligible patients had PROC with ≤2 prior lines of cytotoxic therapy for recurrent or persistent disease. Twenty-six patients were enrolled and given pembrolizumab 200 mg intravenously (IV) every 3 weeks and PLD 40 mg/m2 IV every 4 weeks. Patients were assessed radiographically every 8 weeks. The primary endpoint was clinical benefit rate (CBR), defined as complete response (CR) + partial response (PR) + stable disease (SD) ≥24 weeks. The study was powered to detect an improvement in CBR from 25% to 50%, with rejection of the null hypothesis if at least 10 patients achieved clinical benefit. T-cell inflamed gene expression profiles (GEP) and PD-L1 were assessed and correlated with clinical outcome. RESULTS: Twenty-three patients were evaluable for best overall response. The study satisfied its primary endpoint, with 12 patients achieving clinical benefit for a CBR of 52.2% (95% CI 30.6-73.2%). There were 5 PRs (21.7%) and 1 CR (4.3%), for an overall response rate (ORR) of 26.1%. Six patients had SD lasting at least 24 weeks. Combination therapy was well tolerated without unexpected toxicities. CONCLUSIONS: The combination of pembrolizumab and PLD was manageable, without unexpected toxicities, and showed preliminary evidence of clinical benefit in the treatment of platinum resistant ovarian cancer. ORR and median PFS of combination therapy in this study was higher than historical comparisons of PLD alone or anti-PD-1/PD-L1 agents alone. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02865811.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lee EK, Xiong N, Cheng SC, et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020. PMID: 32771276. doi:10.1016/j.ygyno.2020.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。